DOI: 10.1055/s-00000125

Senologie - Zeitschrift für Mammadiagnostik und -therapie

References

Pivot X, Pegram M, Cortes J. et al
Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2-positive breast cancer.

Eur J Cancer 2019;
120: 1-9

Download Bibliographical Data

Access:
Access:
Access: